Following is the comprehensive index for Volume 31 of IRB: Ethics & Human Research, covering all material from 2009.

The complete citation for each article in the author index is listed under the name of the first author; joint authors are listed alphabetically with a cross reference to the full citation.

Abbreviations used include (BR) Book Review and (L) Letter.

**AUTHOR INDEX**

Albert, Karen, see Lidz, Charles W.


Appelbaum, Paul S. see Lidz, Charles W.

Berkowitz, Howard C., Reassessing “Patient Knowledge,” Vol 31(3) May-Jun 2009, pp. 19-20 (L)

Beskow, Laura M.; Grady, Christine; Ilitis, Ana S.; Sadler, John Z.; and Wilfond, Benjamin S., Points to Consider: The Research Ethics Consultation Service and the IRB, Vol 31(6) Nov-Dec 2009, pp. 1-9

Caligiuri, Michael P. see Henry, James

Carducci, Michael see Kass, Nancy E.

Currie, Peter see Whicher, Danielle

Daugherty, Christopher K. see Kass, Nancy E.

De Vries, Raymond G. see Kim, Scott Y.H.

Emanuel, Ezekiel J. see Koyfman, Shlomo A.

Emerson, Mark R. see Kass, Nancy E.

Fogarty, Linda A. see Kass, Nancy E.

Frank, Samuel A. see Kim, Scott Y.H.

Friedman, Joëlle Y. see Hall, Mark A.

Glorioso, Danielle Kukene see Henry, James

Goodman, Steven N. see Kass, Nancy E.

Goodwin-Landher, Annallys see Kass, Nancy E.

Grady, Christine see Beskow, Laura M.; see Koyfman, Shlomo A.

Hadsksis, Michael R. see Marshall, Jennifer

Hall, Mark A.; Weinfurt, Kevin P.; Lawlor, Janice S.; Friedman, Joëlle Y.; Schulman, Kevin A.; and Sugarman, Jeremy, Community Hospital Oversight of Clinical Investigators’ Financial Relationships, Vol 31(1) Jan-Feb 2009, pp. 7-13

Henry, James; Palmer, Barton W.; Palinkas, Lawrence; Glorioso, Danielle Kukene; Caligiuri, Michael P.; and Jeste, Dilip V., Reformed Consent: Adapting to New Media and Research Participant Preferences, Vol 31(2) Mar-Apr 2009, pp. 1-8

Hlubocky, Fay J. see Kass, Nancy E.

Holloway, Robert G. see Kim, Scott Y.H.

Hurwitz, Herbert I. see Kass, Nancy E.

Ilitis, Ana S. see Beskow, Laura M.


Jeste, Dilip V. see Henry, James

Joffe, Steven see Lidz, Charles W.


Kass, Nancy E. see Taylor, Holly A.

Kieburtz, Karl see Kim, Scott Y.H.


Klitzman, Robert see Appelbaum, Paul S.

Knoppers, Bartha Maria see Wallace, Susan

Koyfman, Shlomo A.; McCabe, Mary S.; Emanuel, Ezekiel J.; and Grady, Christine, A Consent Form Template for Phase I Oncology Trials, Vol 31(4) Jul-Aug 2009, pp. 1-8

Lawlor, Janice S. see Hall, Mark A.

Lazor, Stephanie, see Wallace, Susan

Lidz, Charles W.; Appelbaum, Paul S.; Joffe, Steven; Albert, Karen; Rosenbaum, Jill; and Simon, Lorna, Competing Commitments in Clinical Trials, Vol 31(5) Sept-Oct 2009, pp. 1-6

Lidz, Charles W. see Appelbaum, Paul S.

Marshall, Jennifer, and Hadsksis, Michael R., Canadian Research Ethics Boards: MRI Research Risks,

McCabe, Mary S. see Koyfman, Shlomo A.

Medley, Amy M. see Kass, Nancy E.


Palinkas, Lawrence see Henry, James

Palmer, Barton W. see Henry, James


Rosenbaum, Jill see Lidz, Charles W.

Sadler, John Z. see Beskow, Laura M.

Schonfeld, Toby L. see Anderson, James R.

Schrock, Lauren see Kim, Scott Y.H.

Schulman, Kevin A. see Hall, Mark A.

Simon, Lorna see Lidz, Charles W.

Sugarman, Jeremy see Hall, Mark A.; see Kass, Nancy E.


Wilfond, Benjamin S. see Beskow, Laura M.

Wilson, Renee M. see Kim, Scott Y.H.


SUBJECT INDEX

BIOLOGICAL SAMPLES

CLINICAL TRIALS

Kass, Nancy E. et al., An Intervention to Improve Cancer Patients’ Understanding of Early-Phase Clinical Trials, Vol 31(3) May-Jun 2009, pp. 1-10


Lidz, Charles W. et al., Competing Commitments in Clinical Trials, Vol 31(5) Sept-Oct 2009, pp. 1-6

CLINICAL TRIALS—THERAPEUTIC MISCONCEPTION

CLINICAL TRIALS—THERAPEUTIC OBLIGATION
Lidz, Charles W. et al., Competing Commitments in Clinical Trials, Vol 31(5) Sept-Oct 2009, pp. 1-6

CONFLICTS OF INTEREST
Hall, Mark A. et al., Community Hospital Oversight of Clinical Investigators’ Financial Relationships, Vol 31(1) Jan-Feb 2009, pp. 7-13


DATA SHARING
GENETIC RESEARCH

INFORMED CONSENT
Kass, Nancy E. et al., An Intervention to Improve Cancer Patients’ Understanding of Early-Phase Clinical Trials, Vol 31(3) May-Jun 2009, pp. 1-10

INFORMED CONSENT—COERCION

INFORMED CONSENT—CONSENT FORMS

INFORMED CONSENT—NEW MEDIA

INFORMED CONSENT—VOLUNTARINESS

IRBs—MEMBERSHIP
Whicher, Danielle; Currie, Peter; and Taylor, Holly A., Factors That Influence Institutional Review Board Members’ Commitment to Their Role Responsibilities, Vol 31(5) Sept-Oct 2009, pp. 15-19

IRBs—RESPONSIBILITIES

IRBs—REVIEW
Hall, Mark A. et al., Community Hospital Oversight of Clinical Investigators’ Financial Relationships, Vol 31(1) Jan-Feb 2009, pp. 7-13

JUSTICE
Wall, Anji, Including Persons with Alzheimer Disease in Research on Comorbid Conditions, Vol 31(1) Jan-Feb 2009, pp. 1-6

MRI RESEARCH

RESEARCH DATA

RESEARCH ETHICS CONSULTATION
Whicher, Danielle; Currie, Peter; and Taylor, Holly A., Factors That Influence Institutional Review Board Members’ Commitment to Their Role Responsibilities, Vol 31(5) Sept-Oct 2009, pp. 15-19

RISK/BENEFIT
Kass, Nancy E. et al., An Intervention to Improve Cancer Patients’ Understanding of Early-Phase Clinical Trials, Vol 31(3) May-Jun 2009, pp. 1-10

Wall, Anji, Including Persons with Alzheimer Disease in Research on Comorbid Conditions, Vol 31(1) Jan-Feb 2009, pp. 1-6

**SUBJECTS—VULNERABLE**

Wall, Anji, Including Persons with Alzheimer Disease in Research on Comorbid Conditions, Vol 31(1) Jan-Feb 2009, pp. 1-6

**THERAPEUTIC MISCONCEPTION**


**BOOK REVIEWS**


**LETTERS**

Berkowitz, Howard C., Reassessing “Patient Knowledge,” Vol 31(3) May-Jun 2009, pp. 19-20


**Annotations**

Fry-Revere S, Malmstrom DB. More regulation of industry-supported biomedical research: Are we asking the right questions? Journal of Law, Medicine and Ethics 2009;37(3):420-430. • According to Fry-Revere and Malmstrom, there is not strong evidence to suggest a correlation between industry-supported biomedical research and poor or inappropriate clinical outcomes. Alternatively, they argue that industry having a financial stake in the trial outcomes may in fact lead to better, more careful research. Attempts to limit industry financing of biomedical research could have many negative effects, including making drugs that could save lives less readily available. Critics often falsely conflate conflicts of interest with conflicts of obligations, thus leading some to assume that conflicts of interest are inherently problematic by virtue of the fact that conflicts of obligation can indeed be ethically difficult. The authors suggest patients should be better empowered to ask poignant questions, rather than assuming that physicians always know what is in their best interests.

Rabins P, Appleby BS, Brandt J, et al. Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought. Archives of General Psychiatry 2009; 66(9):931-937. • The authors reported on 16 consensus-created guidelines aimed at the design and implementation of clinical trials related to deep brain stimulation (DBS) for disorders of mood, behavior, and thought (MBT) and the protection of participants of such studies. The guidelines emphasize the need for continued research into the efficacy and safety of DBS in comparison to existing treatments, the importance of multidisciplinary approaches to research, and the establishment of research protocols that are sensitive to the social and cultural perceptions of MBT disorders. In order to ensure appropriate consent, they recommend standardization of forms, the inclusion of a “close third” (such as a caretaker) in the consent process, and full disclosure of what is and is not currently known about DBS. Long-term studies of the safety of DBS and a registry of existing data will help to illuminate the prospects of effective DBS use. The implementation of these guidelines will require long-term commitment from clinicians, investigators, institutions, industry, funders, and government regulatory agencies.

Wynia M, Boren D. Better regulation of industry-sponsored clinical trials is long overdue. Journal of Law, Medicine and Ethics 2009;37(3):410-419. • Wynia and Boren argue that many recent studies show industry-funded trials tend to produce results that favor the company sponsoring the trial as a result of inappropriate trial design and misleading or incomplete analysis and reporting of results. Although regulatory practices—such as better training of clinicians and easier mechanisms for whistle-blowing—may help ensure accountability and safety of clinical trials, there is little to prevent manipulation to increase the likelihood of getting favored results. They contend that the best way to restore trust and promote high-quality, medically relevant clinical trials is to install a professional firewall between industry funding and final decisions about clinical trial design, conduct, analysis, and reporting.